PTC Therapeutics
PTCT
61 hedge funds and large institutions have $262M invested in PTC Therapeutics in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 10 reducing their positions, and 12 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 10
36% more capital inflows, than outflows
Capital inflows: $55.8M | Capital outflows: $41.1M
0% more funds holding
Funds holding: 61 → 61 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
6.07% less ownership
Funds ownership: 56.83% → 50.76% (-6.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$11.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.9M |
| 3 |
RA Capital Management
Boston,
Massachusetts
|
+$7.95M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.32M |
| 5 |
BlackRock Fund Advisors
San Francisco,
California
|
+$4.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HealthCor Management
New York
|
-$15.7M |
| 2 |
Deerfield Management
New York
|
-$5.27M |
| 3 |
Columbus Circle Investors
|
-$4.81M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.99M |
| 5 |
ACM
Ayer Capital Management
San Francisco,
California
|
-$2.72M |
PTCT Hedge Fund Activity: Q4 2013 in Review
61 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2013, worth a combined $262M — down 12% from $297M a quarter earlier.
Fund positioning in PTCT was balanced in Q4 2013: 12 funds opened new positions, 12 closed out, 30 added to existing stakes and 10 trimmed.
The largest buyer was Jennison Associates, adding an estimated $11.8M. The largest seller was HealthCor Management, exiting entirely with an estimated $15.7M sold.
- 61 institutional investors held PTC Therapeutics (PTCT) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $262M of PTC Therapeutics stock for Q4 2013, down 12% quarter-over-quarter.
- 12 funds opened new PTC Therapeutics positions in Q4 2013 and 12 closed out, a net change of 0 holders.
- The largest PTC Therapeutics buyer in Q4 2013 was Jennison Associates, an estimated $11.8M added.
- The largest PTC Therapeutics seller in Q4 2013 was HealthCor Management, an estimated $15.7M sold.
Based on aggregated 13F filings for Q4 2013.